A vaccine for all mankind: Sputnik V’s efficacy in fighting COVID-19 is validated by internationally peer reviewed data published in The Lancet
In an interim analysis of a Phase III clinical trial, Sputnik V showed strong efficacy, immunogenicity and safety results. Efficacy of Sputnik V against COVID-19 was reported at 91.6%. Analysis included data on 19,866 volunteers, who received both the first and second doses of the Sputnik V vaccine or placebo at the final control point …